ArticleThe Journal of infectious diseases2020
Human Immunodeficiency Virus and Hepatitis C Virus Infection Testing Among Commercially Insured Persons Who Inject Drugs, United States, 2010-2017.
Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Rapid, low-cost, and portable molecular detection of HIV-1 subtype B and HCV 1a directly from blood.Microbiology spectrum · 2026Article
- Health care costs associated with disease progression of untreated chronic hepatitis C in the United States.Journal of managed care & specialty pharmacy · 2026Observational
- Health Benefits, Costs, and Cost-Effectiveness of Jail-Based Hepatitis C Elimination Strategies.JAMA internal medicine · 2026Article
- Genomic surveillance uncovers regional variation in HCV transmission networks in rural United States.Nature communications · 2025Article
- Effectiveness of an Embedded Infectious Disease Screening, Treatment, and Prevention Intervention Within an Inpatient Substance Use Treatment Program.Open forum infectious diseases · 2025Article
- Development and Validation of a Machine Learning-Based Screening Algorithm to Predict High-Risk Hepatitis C Infection.Open forum infectious diseases · 2025Article
- Differences in hepatitis C virus (HCV) testing and treatment by opioid, stimulant, and polysubstance use among people who use drugs in rural U.S. communities.Harm reduction journal · 2024Article
- The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections.Drug and alcohol dependence · 2024Article
- Identification of factors associated with opioid-related and hepatitis C virus-related hospitalisations at the ZIP code area level in the USA: an ecological and modelling study.The Lancet. Public health · 2024Article
- Trends in Drug Spending of Oral Anticoagulants for Atrial Fibrillation, 2014-2021.American journal of preventive medicine · 2024Article
- Health, harm reduction, and social service providers' perspectives on the appropriateness and feasibility of peer distribution of HIV self-test kits among people who use drugs.Harm reduction journal · 2024Article
- Willingness to use and distribute HIV self-testing kits among people who inject drugs in the San Diego-Tijuana border region.Harm reduction journal · 2024Article
- Article
- Article
- Hepatitis C Virus-HIV Coinfection in the United States Among People Who Inject Drugs: Data Needed for Ending Dual Epidemics.Public health reports (Washington, D.C. : 1974) · 2023Review
- A study protocol for Project I-Test: a cluster randomized controlled trial of a practice coaching intervention to increase HIV testing in substance use treatment programs.Research square · 2023Article
- Hepatitis C Virus Testing and Care Cascade Among Transgender and Gender Diverse Individuals.American journal of preventive medicine · 2023Article
- The role of community pharmacies in the HIV and HCV care continuum.Exploratory research in clinical and social pharmacy · 2023Article
- Economic Impact of Universal Hepatitis C Virus Testing for Middle-Aged Adults Who Inject Drugs.American journal of preventive medicine · 2023Article
- Behavioral Risk Factors for HIV Infection in Hospitalized Persons Who Co-use Stimulants and Opioids.AIDS and behavior · 2022Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
backgroundWe assessed prevalence of testing for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection among persons who inject drugs (PWID).
methodsUsing a nationwide health insurance database for claims paid during 2010-2017, we identified PWID by using codes from the International Classification of Diseases, Current Procedural Terminology, and National Drug Codes directory. We then estimated the percentage of PWIDs tested for HIV or HCV within 1 year of an index encounter, and we used multivariate logistic regression models to assess demographic and clinical factors associated with testing.
resultsOf 844 242 PWIDs, 71 938 (8.5%) were tested for HIV and 65 188 (7.7%) were tested for HCV infections. Missed opportunities were independently associated with being male (odds ratios [ORs]: HIV, 0.50 [95% confidence interval {CI}, 0.49-0.50], P < .001; HCV, 0.66 [95% CI, 0.65-0.72], P < .001), rural residence (ORs: HIV, 0.67 [95% CI, 0.65-0.69], P < .001; HCV, 0.75 [95% CI, 0.73-0.77], P < .001), and receiving services for skin infections or endocarditis (adjusted ORs: HIV, 0.91 [95% CI, 0.87-0.95], P < .001; HCV, 0.90 [95% CI, 0.86-0.95], P < .001).
conclusionsApproximately 90% of presumed PWIDs missed opportunities for HIV or HCV testing, especially male rural residents with claims for skin infections or endocarditis, commonly associated with injection drug use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.